Academic Journal
View in EDS
HTML Full Text

First-in-human study of ONO-4578, an antagonist of prostaglandin E 2 receptor 4, alone and with nivolumab in solid tumors.

Bibliographic Details
Title: First-in-human study of ONO-4578, an antagonist of prostaglandin E 2 receptor 4, alone and with nivolumab in solid tumors.
Authors: Iwasa S; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan., Koyama T; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan., Nishino M; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan., Kondo S; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan., Sudo K; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan., Yonemori K; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.; Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan., Yoshida T; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.; Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan., Tamura K; Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan., Shimizu T; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan., Fujiwara Y; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan., Kitano S; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan., Shimomura A; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan., Sato J; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan., Yokoyama F; Translational Research Laboratories, Ono Pharmaceutical Co., Ltd., Osaka, Japan., Iida H; Clinical Pharmacology, Ono Pharmaceutical Co., Ltd., Osaka, Japan., Kondo M; Oncology Clinical Development, Ono Pharmaceutical Co., Ltd., Osaka, Japan., Yamamoto N; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
Source: Cancer science [Cancer Sci] 2023 Jan; Vol. 114 (1), pp. 211-220. Date of Electronic Publication: 2022 Nov 04.
Publication Type: Journal Article
Journal Info: Publisher: Wiley Publishing on behalf of the Japanese Cancer Association Country of Publication: England NLM ID: 101168776 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1349-7006 (Electronic) Linking ISSN: 13479032 NLM ISO Abbreviation: Cancer Sci Subsets: MEDLINE
Database: MEDLINE Complete
Full text is not displayed to guests.
Accede al texto completo
Description
ISSN:1349-7006
DOI:10.1111/cas.15574